Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vanderbilt University
With
National Institute of Allergy and Infectious Diseases (NIAID)
No further information. This was a single-arm trial to add an additional anti-diabetic medication to patients already known to be diabetic. The primary endpoint assessed whether the intervention reduced inflammation. There was no control arm.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Body mass index ≥ 25 kg/m2
Glycosylated hemoglobin (A1C) value ≥ 6.5% OR having a fasting blood glucose ≥ 126 mg/dL
On stable antiretroviral therapy for ≥ 12 months (with a fully suppressed plasma HIV-1 RNA level)
Negative serum pregnancy test (females only)
You may not be if
History of pancreatitis
Screening serum lipase value greater than or equal to 2 times the upper limit of normal (≥ 420 U/L)
History of pancreatic cancer or thyroid cancer in patient, a first-degree relative, or a grandparent
History of Multiple Endocrine Neoplasia (MEN) 2 syndrome
History of gastroparesis, inflammatory bowel disease, and/or other severe gastrointestinal disease
